Immunocore’s (IMCR) “Buy” Rating Reiterated at HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $100.00 price target on the stock. HC Wainwright‘s price target suggests a potential upside of 220.56% from the company’s current price.

IMCR has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Mizuho raised their price target on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Morgan Stanley set a $43.00 target price on shares of Immunocore in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research note on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.38.

Immunocore Stock Performance

Shares of IMCR stock traded up $0.22 during trading hours on Monday, reaching $31.20. The stock had a trading volume of 123,386 shares, compared to its average volume of 457,330. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The firm has a 50-day simple moving average of $32.82 and a 200-day simple moving average of $31.66. The firm has a market capitalization of $1.61 billion, a PE ratio of -84.31 and a beta of 0.81.

Immunocore (NASDAQ:IMCR) last released its earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. As a group, equities analysts forecast that Immunocore will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. Rockefeller Capital Management L.P. acquired a new position in Immunocore in the fourth quarter valued at about $47,000. GAMMA Investing LLC lifted its position in Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares in the last quarter. denkapparat Operations GmbH acquired a new position in Immunocore during the 2nd quarter worth about $209,000. Juncture Wealth Strategies LLC acquired a new position in Immunocore during the 3rd quarter worth about $207,000. Finally, Headlands Technologies LLC acquired a new position in Immunocore during the 2nd quarter worth about $290,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.